MAT documentation EHR: recording induction, maintenance and continuity
Medication-assisted treatment generates a record governed by a confidentiality rule stricter than HIPAA. Most electronic systems were designed for HIPAA, and the gap is where practices get into difficulty.
MAT documentation EHR work has to reconcile ordinary clinical record-keeping with 42 CFR Part 2, the confidentiality rule for substance use disorder records. A 2024 rule aligned much of Part 2 with HIPAA, including permitting a single patient consent for treatment, payment and health care operations.
A practice can run an excellent medication-assisted treatment programme and still have a records problem, because the records problem is a different discipline.
The clinical side is well established. The confidentiality side is governed by a rule that predates modern electronic records by decades and was written for a world of separate facilities and paper charts.
That rule changed substantially in 2024, mostly in the direction of workability. What has not changed is that a system built purely for HIPAA does not satisfy it.
What Part 2 protects, and why it is different
Start with scope, because the rule’s reach is narrower and stranger than people assume.
42 CFR Part 2 protects records of the identity, diagnosis, prognosis or treatment of a patient that are maintained in connection with a federally assisted programme for substance use disorder treatment. That is a definition about who holds the record and in what connection, not about the information itself, which is why the same clinical fact can be Part 2 protected in one place and ordinary protected health information in another.
The consequence for a mixed practice is immediate. A primary care practice prescribing buprenorphine may or may not be a Part 2 programme depending on how it holds itself out; an opioid treatment programme certainly is. Answering that question for your own organisation is the first piece of work, and it is a legal question rather than an IT one. We are not going to answer it for you here.
Patient consent, and what the 2024 rule changed
This is the change worth knowing, because it removes the single biggest operational obstacle.
The 2024 final rule on confidentiality of substance use disorder patient records aligned much of Part 2 with HIPAA. The most consequential change is that a patient may give a single consent for all future uses and disclosures for treatment, payment and health care operations, where the previous regime required consent specific to each disclosure.
That is the difference between a rule you can operate at scale and one you cannot. HHS’s fact sheet on the final rule is the clearest short summary. It does not make Part 2 records ordinary records; the redisclosure restrictions and the notice requirements remain. But it removes the pattern where every referral required a new signature.
- Single consent for treatment, payment and health care operations is the change that makes electronic continuity workable. If your consent forms still name each recipient individually, they are built for the previous rule.
Record segmentation and disclosure accounting inside one system
Here is where the rule meets software that was not designed for it.
A HIPAA-designed record has one access model: a user either may see the chart or may not. Part 2 asks for something the model does not naturally express, which is that a specific subset of the record follows different disclosure rules from the rest of it, permanently, including after it leaves.
Systems handle this in one of three ways, and it is worth knowing which yours does. Some segment at the encounter or the department level, which is workable if the programme’s encounters are cleanly separable. Some segment by sensitivity flag on individual elements, which is more precise and much more fragile. And some do not segment at all, in which case the practice is managing the boundary by policy and by where it chooses to record things, which is a legitimate answer provided somebody has written it down.
None of those is wrong. What is wrong is not knowing which one you are relying on, and that is a question EHR consulting can settle in an afternoon.
Continuity of care, and what treatment records are for
It is worth remembering what the confidentiality rule is for, because the compliance framing can obscure it.
Part 2 exists because people will not seek treatment for a substance use disorder if they believe the record will follow them into a job application, a custody dispute or a criminal proceeding. The confidentiality is not bureaucratic overhead; it is a precondition for the treatment happening at all.
That framing also explains why the 2024 changes matter clinically rather than only administratively. A patient on medication-assisted treatment who is admitted to hospital, or who sees a new primary care physician, is safer when that clinician knows what they are taking. A consent regime that made such sharing impractical was protecting the record at the cost of the patient. Making sharing possible with a single properly informed consent serves both.
Not sure whether your system can keep Part 2 records separate?
We work out how your system actually segments, where records leave, and what your consent forms are built for. Written findings, no obligation.
What to check in your own setup
A short list, in the order we would ask it.
- Establish whether you are a Part 2 programme. A legal question, answered once, in writing.
- Check your consent form against the current rule. Per-recipient forms are pre-2024.
- Find out how your system segments. Encounter, element, or not at all.
- Name where records leave. Referrals, labs, pharmacy, registry, billing.
Qventive provides MAT documentation EHR help for medical practices in New Jersey, usually within IT support for addiction treatment practices rather than as a standalone project.
Where segmentation depends on system configuration, that work runs through addiction treatment EHR and IT support, and every disclosure path belongs in your HIPAA risk analysis alongside the Part 2 analysis.
MAT records: common questions
Are we a Part 2 programme?
What changed in the 2024 Part 2 rule?
How should an EHR keep Part 2 records separate?
What are the HIPAA implications alongside Part 2?
Does confidentiality get in the way of good care?
Let’s meet
Qventive supports addiction treatment programmes across New Jersey. Thirty years healthcare-exclusive, from our office in Hackensack.
- Single patient consent permitted for all future uses and disclosures for treatment, payment and health care operations. federalregister.gov
- HHS fact sheet on the 42 CFR Part 2 final rule and its alignment with HIPAA. hhs.gov
- Consent requirements for disclosure of substance use disorder patient records. ecfr.gov